FinnGen provides genetic insights from a well-phenotyped isolated population.


Journal

Nature
ISSN: 1476-4687
Titre abrégé: Nature
Pays: England
ID NLM: 0410462

Informations de publication

Date de publication:
01 2023
Historique:
received: 10 01 2022
accepted: 21 10 2022
entrez: 18 1 2023
pubmed: 19 1 2023
medline: 21 1 2023
Statut: ppublish

Résumé

Population isolates such as those in Finland benefit genetic research because deleterious alleles are often concentrated on a small number of low-frequency variants (0.1% ≤ minor allele frequency < 5%). These variants survived the founding bottleneck rather than being distributed over a large number of ultrarare variants. Although this effect is well established in Mendelian genetics, its value in common disease genetics is less explored

Identifiants

pubmed: 36653562
doi: 10.1038/s41586-022-05473-8
pii: 10.1038/s41586-022-05473-8
pmc: PMC9849126
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

508-518

Commentaires et corrections

Type : CommentIn
Type : ErratumIn

Informations de copyright

© 2023. The Author(s).

Références

Lim, E. T. et al. Distribution and medical impact of loss-of-function variants in the Finnish founder population. PLoS Genet. 10, e1004494 (2014).
pubmed: 25078778 pmcid: 4117444 doi: 10.1371/journal.pgen.1004494
Xue, Y. et al. Enrichment of low-frequency functional variants revealed by whole-genome sequencing of multiple isolated European populations. Nat. Commun. 8, 15927 (2017).
pubmed: 28643794 pmcid: 5490002 doi: 10.1038/ncomms15927
Zuk, O. et al. Searching for missing heritability: designing rare variant association studies. Proc. Natl Acad. Sci. USA https://doi.org/10.1073/pnas.1322563111 (2014).
Norio, R. The Finnish Disease Heritage III: the individual diseases. Hum. Genet. 112, 470–526 (2003).
pubmed: 12627297 doi: 10.1007/s00439-002-0877-1
Auton, A. et al. A global reference for human genetic variation. Nature 526, 68–74 (2015).
pubmed: 26432245 doi: 10.1038/nature15393
Bycroft, C. et al. The UK Biobank resource with deep phenotyping and genomic data. Nature 562, 203–209 (2018).
pubmed: 30305743 pmcid: 6786975 doi: 10.1038/s41586-018-0579-z
Kerminen, S. et al. Fine-scale genetic structure in Finland. G3 7, 3459–3468 (2017).
pubmed: 28983069 pmcid: 5633394 doi: 10.1534/g3.117.300217
Ritari, J., Koskela, S., Hyvärinen, K., FinnGen & Partanen, J. HLA-disease association and pleiotropy landscape in over 235,000 Finns. Hum. Immunol. 83, 391–398 (2022).
Karczewski, K. J. et al. The mutational constraint spectrum quantified from variation in 141,456 humans. Nature 581, 434–443 (2020).
pubmed: 32461654 pmcid: 7334197 doi: 10.1038/s41586-020-2308-7
Kanai, M. et al. Insights from complex trait fine-mapping across diverse populations. Preprint at medRxiv https://doi.org/10.1101/2021.09.03.21262975 (2021).
Sakaue, S. et al. A cross-population atlas of genetic associations for 220 human phenotypes. Nat. Genet. 53, 1415–1424 (2021).
pubmed: 34594039 doi: 10.1038/s41588-021-00931-x
Sun, B. B. et al. Genetic associations of protein-coding variants in human disease. Nature 603, 95–102 (2022).
pubmed: 35197637 pmcid: 8891017 doi: 10.1038/s41586-022-04394-w
Heyne, H. O. et al. Mono- and biallelic effects of on disease at biobank scale. Nature https://doi.org/10.1038/s41586-022-05420-7 (2022).
Patel, K. A. et al. Heterozygous RFX6 protein truncating variants are associated with MODY with reduced penetrance. Nat. Commun. 8, 888 (2017).
pubmed: 29026101 pmcid: 5638866 doi: 10.1038/s41467-017-00895-9
Norberg, A. et al. Novel variants in Nordic patients referred for genetic testing of telomere-related disorders. Eur. J. Hum. Genet. 26, 858–867 (2018).
pubmed: 29483670 pmcid: 5974393 doi: 10.1038/s41431-018-0112-8
Löf, C. et al. Detection of novel gene variants associated with congenital hypothyroidism in a Finnish patient cohort. Thyroid 26, 1215–1224 (2016).
pubmed: 27373559 pmcid: 5036323 doi: 10.1089/thy.2016.0016
Jiang, X.-C. & Yu, Y. The role of phospholipid transfer protein in the development of atherosclerosis. Curr. Atheroscler. Rep. 23, 9 (2021).
pubmed: 33496859 pmcid: 8006745 doi: 10.1007/s11883-021-00907-6
Teslovich, T. M. et al. Biological, clinical, and population relevance of 95 loci for blood lipids. Nature 466, 707–713 (2010).
pubmed: 20686565 pmcid: 3039276 doi: 10.1038/nature09270
van der Harst, P. & Verweij, N. Identification of 64 novel genetic loci provides an expanded view on the genetic architecture of coronary artery disease. Circ. Res. 122, 433–443 (2018).
pubmed: 29212778 pmcid: 5805277 doi: 10.1161/CIRCRESAHA.117.312086
Shadrina, A. S. et al. Prioritization of causal genes for coronary artery disease based on cumulative evidence from experimental and in silico studies. Sci. Rep. 10, 10486 (2020).
pubmed: 32591598 pmcid: 7320185 doi: 10.1038/s41598-020-67001-w
Dimitra, A. et al. HHIPL1, a gene at the 14q32 coronary artery disease locus, positively regulates hedgehog signaling and promotes atherosclerosis. Circulation 140, 500–513 (2019).
doi: 10.1161/CIRCULATIONAHA.119.041059
Bindesbøll, C. et al. NBEAL1 controls SREBP2 processing and cholesterol metabolism and is a susceptibility locus for coronary artery disease. Sci. Rep. 10, 4528 (2020).
pubmed: 32161285 pmcid: 7066131 doi: 10.1038/s41598-020-61352-0
Graydon, C. G., Mohideen, S. & Fowke, K. R. LAG3’s enigmatic mechanism of action. Front. Immunol. https://doi.org/10.3389/fimmu.2020.615317 (2021).
FDA approves anti-LAG3 checkpoint. Nat. Biotechnol. 40, 625 (2022).
doi: 10.1038/s41587-022-01331-0
Boer, C. G. et al. Deciphering osteoarthritis genetics across 826,690 individuals from 9 populations. Cell 184, 4784–4818.e17 (2021).
pubmed: 34450027 pmcid: 8459317 doi: 10.1016/j.cell.2021.07.038
Sliz, E. et al. Uniting biobank resources reveals novel genetic pathways modulating susceptibility for atopic dermatitis. J. Allergy Clin. Immunol. 149, 1105–1112.e9 (2022).
pubmed: 34454985 doi: 10.1016/j.jaci.2021.07.043
Li, J. et al. Utility of basophil activation test for predicting the outcome of wheezing in children: a pilot study. BMC Immunol. 22, 4 (2021).
pubmed: 33407109 pmcid: 7788708 doi: 10.1186/s12865-020-00395-4
Chakraborti, S., Natarajan, K., Curiel, J., Janke, C. & Liu, J. The emerging role of the tubulin code: from the tubulin molecule to neuronal function and disease. Cytoskeleton 73, 521–550 (2016).
pubmed: 26934450 doi: 10.1002/cm.21290
Sharifinejad, N. et al. Clinical, immunological, and genetic features in 49 patients with ZAP-70 deficiency: a systematic review. Front. Immunol. 11, 831 (2020).
pubmed: 32431715 pmcid: 7214800 doi: 10.3389/fimmu.2020.00831
Mulford, A. J., Wing, C., Dolan, M. E. & Wheeler, H. E. Genetically regulated expression underlies cellular sensitivity to chemotherapy in diverse populations. Hum. Mol. Genet. 30, 305–317 (2021).
pubmed: 33575800 pmcid: 8248963 doi: 10.1093/hmg/ddab029
Mafra, F. et al. Copy number variation analysis reveals additional variants contributing to endometriosis development. J. Assist. Reprod. Genet. 34, 117–124 (2017).
pubmed: 27817035 doi: 10.1007/s10815-016-0822-1
Koskela, J. T. et al. Genetic variant in SPDL1 reveals novel mechanism linking pulmonary fibrosis risk and cancer protection. Preprint at medRxiv https://doi.org/10.1101/2021.05.07.21255988 (2021).
Ruotsalainen, S. E. et al. Inframe insertion and splice site variants in MFGE8 associate with protection against coronary atherosclerosis. Commun. Biol. 5, 802 (2022).
pubmed: 35978133 pmcid: 9385630 doi: 10.1038/s42003-022-03552-0
Rämö, J. T. et al. Genome-wide screen of otosclerosis in population biobanks: 27 loci and shared associations with skeletal structure. Nat. Commun. https://doi.org/10.1038/s41467-022-32936-3 (2023).
Tanigawa, Y. et al. Rare protein-altering variants in ANGPTL7 lower intraocular pressure and protect against glaucoma. PLoS Genet. 16, e1008682 (2020).
pubmed: 32369491 pmcid: 7199928 doi: 10.1371/journal.pgen.1008682
Surakka, I. et al. The impact of low-frequency and rare variants on lipid levels. Nat. Genet. 47, 589–597 (2015).
pubmed: 25961943 pmcid: 4757735 doi: 10.1038/ng.3300
Ehrhardt, N. et al. Hepatic Tm6sf2 overexpression affects cellular ApoB-trafficking, plasma lipid levels, hepatic steatosis and atherosclerosis. Hum. Mol. Genet. 26, 2719–2731 (2017).
pubmed: 28449094 pmcid: 5886214 doi: 10.1093/hmg/ddx159
Prill, S. et al. The TM6SF2 E167K genetic variant induces lipid biosynthesis and reduces apolipoprotein B secretion in human hepatic 3D spheroids. Sci. Rep. 9, 11585 (2019).
pubmed: 31406127 pmcid: 6690969 doi: 10.1038/s41598-019-47737-w
Pirola, C. J. & Sookoian, S. The dual and opposite role of the TM6SF2-rs58542926 variant in protecting against cardiovascular disease and conferring risk for nonalcoholic fatty liver: a meta-analysis. Hepatology 62, 1742–1756 (2015).
pubmed: 26331730 doi: 10.1002/hep.28142
Buch, S. et al. A genome-wide association study confirms PNPLA3 and identifies TM6SF2 and MBOAT7 as risk loci for alcohol-related cirrhosis. Nat. Genet. 47, 1443–1448 (2015).
pubmed: 26482880 doi: 10.1038/ng.3417
Tang, S. et al. Association of TM6SF2 rs58542926 T/C gene polymorphism with hepatocellular carcinoma: a meta-analysis. BMC Cancer 19, 1128 (2019).
pubmed: 31752753 pmcid: 6868855 doi: 10.1186/s12885-019-6173-4
Kim, D. S. et al. Novel association of TM6SF2 rs58542926 genotype with increased serum tyrosine levels and decreased apoB-100 particles in Finns. J. Lipid Res. 58, 1471–1481 (2017).
pubmed: 28539357 pmcid: 5496043 doi: 10.1194/jlr.P076034
Mars, N. et al. Polygenic and clinical risk scores and their impact on age at onset and prediction of cardiometabolic diseases and common cancers. Nat. Med. 26, 549–557 (2020).
pubmed: 32273609 doi: 10.1038/s41591-020-0800-0
Kiiskinen, T. et al. Genomic prediction of alcohol-related morbidity and mortality. Transl Psychiatry 10, 23 (2020).
pubmed: 32066667 pmcid: 7026428 doi: 10.1038/s41398-019-0676-2
Strausz, S. et al. Genetic analysis of obstructive sleep apnoea discovers a strong association with cardiometabolic health. Eur. Respir. J. 57, 2003091 (2021).
pubmed: 33243845 doi: 10.1183/13993003.03091-2020
Helkkula, P. et al. ANGPTL8 protein-truncating variant associated with lower serum triglycerides and risk of coronary disease. PLoS Genet. 17, e1009501 (2021).
Rahimov, F. et al. High incidence and regional distribution of cleft palate in Finns are associated with a functional variant in an IRF6 enhancer. Preprint at Research Square https://doi.org/10.21203/rs.3.rs-941741/v1 (2021).
Niemi, M. E. K. et al. Mapping the human genetic architecture of COVID-19. Nature https://doi.org/10.1038/s41586-021-03767-x (2021).
Zhou, W. et al. Global Biobank Meta-analysis Initiative: powering genetic discovery across human disease. Cell Genom. 2, 100192 (2022).
Broekema, R. V., Bakker, O. B. & Jonkers, I. H. A practical view of fine-mapping and gene prioritization in the post-genome-wide association era. Open Biol. 10, 190221 (2020).
pubmed: 31937202 pmcid: 7014684 doi: 10.1098/rsob.190221
Fry, A. et al. Comparison of sociodemographic and health-related characteristics of UK Biobank participants with those of the general population. Am. J. Epidemiol. 186, 1026–1034 (2017).
pubmed: 28641372 pmcid: 5860371 doi: 10.1093/aje/kwx246
Pärn, K. et al. Genotyping chip data lift-over to reference genome build GRCh38/hg38 V.2. protocols.io https://doi.org/10.17504/protocols.io.nqtddwn (2019).
Palta, P. Genotype imputation workflow v3.0 V.1. protocols.io https://doi.org/10.17504/protocols.io.nmndc5e (2018).
Zhou, W. et al. Efficiently controlling for case–control imbalance and sample relatedness in large-scale genetic association studies. Nat. Genet. 50, 1335–1341 (2018).
pubmed: 30104761 pmcid: 6119127 doi: 10.1038/s41588-018-0184-y
Wang, G., Sarkar, A., Carbonetto, P. & Stephens, M. A simple new approach to variable selection in regression, with application to genetic fine mapping. J. R. Stat. Soc. Ser. B Stat. Methodol. 82, 1273–1300 (2020).
doi: 10.1111/rssb.12388
Gagliano Taliun, S. A. Exploring and visualizing large-scale genetic associations by using PheWeb. Nat. Genet. 52, 550–552 (2020).
pubmed: 32504056 pmcid: 7754083 doi: 10.1038/s41588-020-0622-5
Mitt, M. et al. Improved imputation accuracy of rare and low-frequency variants using population-specific high-coverage WGS-based imputation reference panel. Eur. J. Hum. Genet. 25, 869–876 (2017).
pubmed: 28401899 pmcid: 5520064 doi: 10.1038/ejhg.2017.51
Pan-UK Biobank (Pan UK Biobank Team, 2020); https://pan.ukbb.broadinstitute.org .
Hail v.0.2 (Hail Team, 2019); https://github.com/hail-is/hail .
Hormozdiari, F. et al. Colocalization of GWAS and eQTL signals detects target genes. Am. J. Hum. Genet. 99, 1245–1260 (2016).
pubmed: 27866706 pmcid: 5142122 doi: 10.1016/j.ajhg.2016.10.003
Kerimov, N. et al. A compendium of uniformly processed human gene expression and splicing quantitative trait loci. Nat. Genet. 53, 1290–1299 (2021).
pubmed: 34493866 pmcid: 8423625 doi: 10.1038/s41588-021-00924-w
Ochoa, D. et al. Open Targets Platform: supporting systematic drug–target identification and prioritisation. Nucleic Acids Res. 49, D1302–D1310 (2021).
pubmed: 33196847 doi: 10.1093/nar/gkaa1027
Landrum, M. J. et al. ClinVar: improving access to variant interpretations and supporting evidence. Nucleic Acids Res. 46, D1062–D1067 (2018).
pubmed: 29165669 doi: 10.1093/nar/gkx1153
Buniello, A. et al. The NHGRI-EBI GWAS Catalog of published genome-wide association studies, targeted arrays and summary statistics 2019. Nucleic Acids Res. 47, D1005–D1012 (2019).
pubmed: 30445434 doi: 10.1093/nar/gky1120

Auteurs

Mitja I Kurki (MI)

Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Helsinki, Finland.
Program in Medical and Population Genetics, Broad Institute of Harvard and MIT, Cambridge, MA, USA.
Stanley Center for Psychiatric Research, Broad Institute of Harvard and MIT, Cambridge, MA, USA.
Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston, MA, USA.

Juha Karjalainen (J)

Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Helsinki, Finland.
Program in Medical and Population Genetics, Broad Institute of Harvard and MIT, Cambridge, MA, USA.
Stanley Center for Psychiatric Research, Broad Institute of Harvard and MIT, Cambridge, MA, USA.
Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston, MA, USA.

Priit Palta (P)

Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Helsinki, Finland.
Estonian Genome Centre, Institute of Genomics, University of Tartu, Tartu, Estonia.

Timo P Sipilä (TP)

Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Helsinki, Finland.

Kati Kristiansson (K)

Finnish Institute for Health and Welfare (THL), Helsinki, Finland.

Kati M Donner (KM)

Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Helsinki, Finland.

Mary P Reeve (MP)

Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Helsinki, Finland.

Hannele Laivuori (H)

Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Helsinki, Finland.
Medical and Clinical Genetics, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Department of Obstetrics and Gynecology, Tampere University Hospital, Tampere, Finland.
Faculty of Medicine and Health Technology, Center for Child, Adolescent and Maternal Health, University of Tampere, Tampere, Finland.

Mervi Aavikko (M)

Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Helsinki, Finland.

Mari A Kaunisto (MA)

Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Helsinki, Finland.

Anu Loukola (A)

Helsinki Biobank, University of Helsinki and Hospital District of Helsinki and Uusimaa, Helsinki, Finland.

Elisa Lahtela (E)

Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Helsinki, Finland.

Hannele Mattsson (H)

Finnish Institute for Health and Welfare (THL), Helsinki, Finland.

Päivi Laiho (P)

Finnish Institute for Health and Welfare (THL), Helsinki, Finland.

Pietro Della Briotta Parolo (P)

Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Helsinki, Finland.

Arto A Lehisto (AA)

Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Helsinki, Finland.

Masahiro Kanai (M)

Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Helsinki, Finland.
Program in Medical and Population Genetics, Broad Institute of Harvard and MIT, Cambridge, MA, USA.
Stanley Center for Psychiatric Research, Broad Institute of Harvard and MIT, Cambridge, MA, USA.
Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston, MA, USA.
Department of Biomedical Informatics, Harvard Medical School, Boston, MA, USA.

Nina Mars (N)

Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Helsinki, Finland.

Joel Rämö (J)

Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Helsinki, Finland.

Tuomo Kiiskinen (T)

Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Helsinki, Finland.

Henrike O Heyne (HO)

Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Helsinki, Finland.
Program in Medical and Population Genetics, Broad Institute of Harvard and MIT, Cambridge, MA, USA.
Stanley Center for Psychiatric Research, Broad Institute of Harvard and MIT, Cambridge, MA, USA.
Digital Health Center, Hasso Plattner Institute for Digital Engineering, University of Potsdam Potsdam, Potsdam, Germany.
Hasso Plattner Institute for Digital Health at Mount Sinai, Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Kumar Veerapen (K)

Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Helsinki, Finland.
Program in Medical and Population Genetics, Broad Institute of Harvard and MIT, Cambridge, MA, USA.
Stanley Center for Psychiatric Research, Broad Institute of Harvard and MIT, Cambridge, MA, USA.
Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston, MA, USA.

Sina Rüeger (S)

Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Helsinki, Finland.

Susanna Lemmelä (S)

Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Helsinki, Finland.
Finnish Institute for Health and Welfare (THL), Helsinki, Finland.

Wei Zhou (W)

Program in Medical and Population Genetics, Broad Institute of Harvard and MIT, Cambridge, MA, USA.
Stanley Center for Psychiatric Research, Broad Institute of Harvard and MIT, Cambridge, MA, USA.
Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston, MA, USA.

Sanni Ruotsalainen (S)

Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Helsinki, Finland.

Kalle Pärn (K)

Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Helsinki, Finland.

Tero Hiekkalinna (T)

Finnish Institute for Health and Welfare (THL), Helsinki, Finland.

Sami Koskelainen (S)

Finnish Institute for Health and Welfare (THL), Helsinki, Finland.

Teemu Paajanen (T)

Finnish Institute for Health and Welfare (THL), Helsinki, Finland.

Vincent Llorens (V)

Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Helsinki, Finland.

Javier Gracia-Tabuenca (J)

TAUCHI Research Center, Faculty of Information Technology and Communication Sciences, Tampere University, Tampere, Finland.

Harri Siirtola (H)

TAUCHI Research Center, Faculty of Information Technology and Communication Sciences, Tampere University, Tampere, Finland.

Kadri Reis (K)

Estonian Genome Centre, Institute of Genomics, University of Tartu, Tartu, Estonia.

Abdelrahman G Elnahas (AG)

Estonian Genome Centre, Institute of Genomics, University of Tartu, Tartu, Estonia.

Benjamin Sun (B)

Translational Biology, Research and Development, Biogen, Cambridge, MA, USA.
BHF Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.

Christopher N Foley (CN)

Optima Partners, Edinburgh, UK.
MRC Biostatistics Unit, School of Clinical Medicine, University of Cambridge, Cambridge, UK.

Katriina Aalto-Setälä (K)

Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.

Kaur Alasoo (K)

Institute of Computer Science, University of Tartu, Tartu, Estonia.

Mikko Arvas (M)

Finnish Red Cross Blood Service, Helsinki, Finland.

Kirsi Auro (K)

GlaxoSmithKline, Espoo, Finland.

Shameek Biswas (S)

Bristol Myers Squibb, New York, NY, USA.

Argyro Bizaki-Vallaskangas (A)

Tampere University Hospital and Tampere University, Tampere, Finland.

Olli Carpen (O)

Helsinki Biobank, University of Helsinki and Hospital District of Helsinki and Uusimaa, Helsinki, Finland.

Chia-Yen Chen (CY)

Biogen, Cambridge, MA, USA.

Oluwaseun A Dada (OA)

Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Helsinki, Finland.

Zhihao Ding (Z)

Boehringer Ingelheim, Ingelheim am Rhein, Germany.

Margaret G Ehm (MG)

GlaxoSmithKline, Collegeville, PA, USA.

Kari Eklund (K)

Division of Rheumatology, Department of Medicine, Helsinki University Central Hospital, Helsinki, Finland.
Orton Orthopedic Hospital, Helsinki, Finland.

Martti Färkkilä (M)

Abdominal Center, Helsinki University Hospital, Helsinki University, Helsinki, Finland.

Hilary Finucane (H)

Program in Medical and Population Genetics, Broad Institute of Harvard and MIT, Cambridge, MA, USA.
Stanley Center for Psychiatric Research, Broad Institute of Harvard and MIT, Cambridge, MA, USA.
Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston, MA, USA.

Andrea Ganna (A)

Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Helsinki, Finland.
Program in Medical and Population Genetics, Broad Institute of Harvard and MIT, Cambridge, MA, USA.
Stanley Center for Psychiatric Research, Broad Institute of Harvard and MIT, Cambridge, MA, USA.
Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston, MA, USA.

Awaisa Ghazal (A)

Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Helsinki, Finland.

Robert R Graham (RR)

Maze Therapeutics, South San Francisco, CA, USA.

Eric M Green (EM)

Maze Therapeutics, South San Francisco, CA, USA.

Antti Hakanen (A)

Auria Biobank, University of Turku and Turku University Hospital, Turku, Finland.

Marco Hautalahti (M)

FINBB, Finnish Biobank Cooperative, Helsinki, Finland.

Åsa K Hedman (ÅK)

Pfizer, New York, NY, USA.
Department of Medicine, Karolinska Institute, Solna, Sweden.

Mikko Hiltunen (M)

Clinical Biobank Tampere, Tampere University and Tampere University Hospital, Tampere, Finland.

Reetta Hinttala (R)

Medical Research Center Oulu and PEDEGO Research Unit, University of Oulu, Oulu, Finland.
Biocenter Oulu, University of Oulu, Oulu, Finland.
Oulu University Hospital, Oulu, Finland.

Iiris Hovatta (I)

Department of Psychology and Logopedics, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
SleepWell Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.

Xinli Hu (X)

Pfizer, New York, NY, USA.

Adriana Huertas-Vazquez (A)

Merck & Co, Kenilworth, NJ, USA.

Laura Huilaja (L)

PEDEGO Research Unit, University of Oulu, Oulu, Finland.
Department of Dermatology and Medical Research Center Oulu, Oulu University Hospital, Oulu, Finland.

Julie Hunkapiller (J)

Genentech, San Francisco, CA, USA.

Howard Jacob (H)

AbbVie, Chicago, IL, USA.

Jan-Nygaard Jensen (JN)

Boehringer Ingelheim, Ingelheim am Rhein, Germany.

Heikki Joensuu (H)

Helsinki University Hospital and University of Helsinki, Helsinki, Finland.

Sally John (S)

Biogen, Cambridge, MA, USA.

Valtteri Julkunen (V)

Neuro Center, Neurology, Kuopio University Hospital, Kuopio, Finland.
Institute of Clinical Medicine-Neurology, University of Eastern Finland, Kuopio, Finland.

Marc Jung (M)

Boehringer Ingelheim, Ingelheim am Rhein, Germany.

Juhani Junttila (J)

Northern Finland Biobank Borealis, University of Oulu, Northern Ostrobothnia Hospital District, Oulu, Finland.

Kai Kaarniranta (K)

Department of Ophthalmology, Kuopio University Hospital, Kuopio, Finland.
Department of Ophthalmology, Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland.

Mika Kähönen (M)

Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.
Department of Clinical Physiology, Tampere University Hospital, Tampere, Finland.

Risto Kajanne (R)

Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Helsinki, Finland.

Lila Kallio (L)

Auria Biobank, University of Turku and Turku University Hospital, Turku, Finland.

Reetta Kälviäinen (R)

Epilepsy Center, Kuopio University Hospital, Kuopio, Finland.
Department of Neurology, University of Eastern Finland, Kuopio, Finland.

Jaakko Kaprio (J)

Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Helsinki, Finland.
Department of Public Health, University of Helsinki, Helsinki, Finland.

Nurlan Kerimov (N)

Institute of Computer Science, University of Tartu, Tartu, Estonia.

Johannes Kettunen (J)

Finnish Institute for Health and Welfare (THL), Helsinki, Finland.
Biocenter Oulu, University of Oulu, Oulu, Finland.
Computational Medicine, Center for Life Course Health Research, Faculty of Medicine, University of Oulu, Oulu, Finland.

Elina Kilpeläinen (E)

Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Helsinki, Finland.

Terhi Kilpi (T)

Finnish Institute for Health and Welfare (THL), Helsinki, Finland.

Katherine Klinger (K)

Translational Sciences, Sanofi R&D, Framingham, MA, USA.

Veli-Matti Kosma (VM)

Biobank of Eastern Finland, University of Eastern Finland, Kuopio, Finland.
Kuopio University Hospital, Kuopio, Finland.

Teijo Kuopio (T)

Central Finland Biobank, Central Finland Health Care District, Jyväskylä, Finland.

Venla Kurra (V)

Department of Clinical Genetics, Tampere University Hospital, Tampere, Finland.
Department of Clinical Genetics, Faculty of Medicine and Health Technology, Tampere, Finland.

Triin Laisk (T)

Estonian Genome Centre, Institute of Genomics, University of Tartu, Tartu, Estonia.

Jari Laukkanen (J)

Central Finland Biobank, Central Finland Health Care District, Jyväskylä, Finland.
Department of Medicine, Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland.

Nathan Lawless (N)

Boehringer Ingelheim, Ingelheim am Rhein, Germany.

Aoxing Liu (A)

Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Helsinki, Finland.

Simonne Longerich (S)

Merck & Co, Kenilworth, NJ, USA.

Reedik Mägi (R)

Estonian Genome Centre, Institute of Genomics, University of Tartu, Tartu, Estonia.

Johanna Mäkelä (J)

FINBB, Finnish Biobank Cooperative, Turku, Finland.

Antti Mäkitie (A)

Department of Otorhinolaryngology-Head and Neck Surgery, University of Helsinki, Helsinki, Finland.
Helsinki University Hospital, Helsinki, Finland.

Anders Malarstig (A)

Pfizer, Cambridge, MA, USA.
Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Solna, Sweden.

Arto Mannermaa (A)

Biobank of Eastern Finland, University of Eastern Finland, Kuopio, Finland.
Kuopio University Hospital, Kuopio, Finland.

Joseph Maranville (J)

Bristol Myers Squibb, New York, NY, USA.

Athena Matakidou (A)

Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.

Tuomo Meretoja (T)

Helsinki University Hospital and University of Helsinki, Helsinki, Finland.

Sahar V Mozaffari (SV)

Maze Therapeutics, South San Francisco, CA, USA.

Mari E K Niemi (MEK)

Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Helsinki, Finland.

Marianna Niemi (M)

Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.
TAUCHI Research Center & Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.

Teemu Niiranen (T)

Finnish Institute for Health and Welfare (THL), Helsinki, Finland.
Turku University Hospital and University of Turku, Turku, Finland.

Christopher J O Donnell (CJ)

Novartis Institutes for BioMedical Research, Cambridge, MA, USA.

Ma En Obeidat (ME)

Novartis Institutes for BioMedical Research, Cambridge, MA, USA.

George Okafo (G)

Boehringer Ingelheim, Ingelheim am Rhein, Germany.

Hanna M Ollila (HM)

Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Helsinki, Finland.
Anesthesia, Critical Care, and Pain Medicine, Massachusetts General Hospital, Boston, MA, USA.

Antti Palomäki (A)

Turku University Hospital and University of Turku, Turku, Finland.

Tuula Palotie (T)

Department of Oral and Maxillofacial Diseases, Helsinki University Hospital, Helsinki, Finland.
Department of Oral and Maxillofacial Diseases, University of Helsinki, Helsinki, Finland.

Jukka Partanen (J)

Finnish Red Cross Blood Service, Helsinki, Finland.
Finnish Hematological Biobank, Helsinki, Finland.

Dirk S Paul (DS)

Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.

Margit Pelkonen (M)

Department of Pulmonary Diseases, Kuopio University Hospital, Kuopio, Finland.

Rion K Pendergrass (RK)

Genentech, San Francisco, CA, USA.

Slavé Petrovski (S)

Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.

Anne Pitkäranta (A)

Department of Otorhinolaryngology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.

Adam Platt (A)

Translational Science and Experimental Medicine, Research and Early Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.

David Pulford (D)

GlaxoSmithKline, Stevenage, UK.

Eero Punkka (E)

Helsinki Biobank, University of Helsinki and Hospital District of Helsinki and Uusimaa, Helsinki, Finland.

Pirkko Pussinen (P)

Department of Oral and Maxillofacial Diseases, University of Helsinki, Helsinki, Finland.

Neha Raghavan (N)

Merck & Co, Kenilworth, NJ, USA.

Fedik Rahimov (F)

AbbVie, Chicago, IL, USA.

Deepak Rajpal (D)

Translational Sciences, Sanofi R&D, Framingham, MA, USA.

Nicole A Renaud (NA)

Novartis Institutes for BioMedical Research, Cambridge, MA, USA.

Bridget Riley-Gillis (B)

AbbVie, Chicago, IL, USA.

Rodosthenis Rodosthenous (R)

Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Helsinki, Finland.

Elmo Saarentaus (E)

Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Helsinki, Finland.

Aino Salminen (A)

Department of Oral and Maxillofacial Diseases, University of Helsinki, Helsinki, Finland.

Eveliina Salminen (E)

Helsinki University Hospital, Helsinki, Finland.
Department of Clinical Genetics, HUSLAB, HUS Diagnostic Center, University of Helsinki, Helsinki, Finland.

Veikko Salomaa (V)

Finnish Institute for Health and Welfare (THL), Helsinki, Finland.

Johanna Schleutker (J)

Auria Biobank, University of Turku and Turku University Hospital, Turku, Finland.

Raisa Serpi (R)

Northern Finland Biobank Borealis, University of Oulu, Northern Ostrobothnia Hospital District, Oulu, Finland.

Huei-Yi Shen (HY)

Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Helsinki, Finland.

Richard Siegel (R)

Novartis Institutes for BioMedical Research, Basel, Switzerland.

Kaisa Silander (K)

Finnish Institute for Health and Welfare (THL), Helsinki, Finland.

Sanna Siltanen (S)

Finnish Clinical Biobank Tampere, Tampere University and Tampere University Hospital, Tampere, Finland.

Sirpa Soini (S)

Finnish Institute for Health and Welfare (THL), Helsinki, Finland.

Hilkka Soininen (H)

Department of Neurology, Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland.

Jae Hoon Sul (JH)

Merck & Co, Kenilworth, NJ, USA.

Ioanna Tachmazidou (I)

Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.

Kaisa Tasanen (K)

PEDEGO Research Unit, University of Oulu, Oulu, Finland.
Department of Dermatology and Medical Research Center Oulu, Oulu University Hospital, Oulu, Finland.

Pentti Tienari (P)

Department of Neurology, Helsinki University Hospital, Helsinki, Finland.
Translational Immunology, Research Programs Unit, University of Helsinki, Helsinki, Finland.

Sanna Toppila-Salmi (S)

Department of Allergy, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.

Taru Tukiainen (T)

Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Helsinki, Finland.

Tiinamaija Tuomi (T)

Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Helsinki, Finland.
Abdominal Center, Endocrinology, Helsinki University Hospital, Helsinki, Finland.
Folkhalsan Research Center, Helsinki, Finland.
Research Program of Clinical and Molecular Metabolism, University of Helsinki, Helsinki, Finland.

Joni A Turunen (JA)

Helsinki University Hospital and University of Helsinki, Helsinki, Finland.
Eye Genetics Group, Folkhälsan Research Center, Helsinki, Finland.

Jacob C Ulirsch (JC)

Program in Medical and Population Genetics, Broad Institute of Harvard and MIT, Cambridge, MA, USA.
Stanley Center for Psychiatric Research, Broad Institute of Harvard and MIT, Cambridge, MA, USA.

Felix Vaura (F)

Finnish Institute for Health and Welfare (THL), Helsinki, Finland.
University of Turku, Turku, Finland.

Petri Virolainen (P)

Auria Biobank, University of Turku and Turku University Hospital, Turku, Finland.

Jeffrey Waring (J)

AbbVie, Chicago, IL, USA.

Dawn Waterworth (D)

Janssen Research & Development, Spring House, PA, USA.

Robert Yang (R)

Janssen Biotech, Beerse, Belgium.

Mari Nelis (M)

Genomics Core Facility, Institute of Genomics, University of Tartu, Tartu, Estonia.

Anu Reigo (A)

Estonian Genome Centre, Institute of Genomics, University of Tartu, Tartu, Estonia.

Andres Metspalu (A)

Estonian Genome Centre, Institute of Genomics, University of Tartu, Tartu, Estonia.

Lili Milani (L)

Estonian Genome Centre, Institute of Genomics, University of Tartu, Tartu, Estonia.

Tõnu Esko (T)

Estonian Genome Centre, Institute of Genomics, University of Tartu, Tartu, Estonia.

Caroline Fox (C)

Merck & Co, Kenilworth, NJ, USA.

Aki S Havulinna (AS)

Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Helsinki, Finland.
Finnish Institute for Health and Welfare (THL), Helsinki, Finland.

Markus Perola (M)

Finnish Institute for Health and Welfare (THL), Helsinki, Finland.

Samuli Ripatti (S)

Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Helsinki, Finland.

Anu Jalanko (A)

Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Helsinki, Finland.

Tarja Laitinen (T)

Finnish Clinical Biobank Tampere, Tampere University and Tampere University Hospital, Tampere, Finland.

Tomi P Mäkelä (TP)

Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Helsinki, Finland.

Robert Plenge (R)

Bristol Myers Squibb, New York, NY, USA.

Mark McCarthy (M)

Genentech, San Francisco, CA, USA.

Heiko Runz (H)

Biogen, Cambridge, MA, USA.

Mark J Daly (MJ)

Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Helsinki, Finland.
Program in Medical and Population Genetics, Broad Institute of Harvard and MIT, Cambridge, MA, USA.
Stanley Center for Psychiatric Research, Broad Institute of Harvard and MIT, Cambridge, MA, USA.
Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston, MA, USA.

Aarno Palotie (A)

Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Helsinki, Finland. aarno.palotie@helsinki.fi.
Program in Medical and Population Genetics, Broad Institute of Harvard and MIT, Cambridge, MA, USA. aarno.palotie@helsinki.fi.
Stanley Center for Psychiatric Research, Broad Institute of Harvard and MIT, Cambridge, MA, USA. aarno.palotie@helsinki.fi.
Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston, MA, USA. aarno.palotie@helsinki.fi.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH